Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03879096
Other study ID # ClubCam
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 1, 2016
Est. completion date May 31, 2023

Study information

Verified date May 2020
Source University of Malaga
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim is to analyse the effect of a Therapeutic Exercise and Education programme in several clinical and functional outcomes in cancer patient and survivors


Description:

In the oncology field, both patients and survivors have to face several symptoms, like cancer-related fatigue or pain. Cancer patients also have affected quality of life, lower levels of function and they are at higher risk of weight gain following diagnosis. Given the risk of obesity, both exercise and diet play a key role in recovery from cancer. Hence, the aim of this study is to show the effect of a Therapeutic Exercise and Education programme (TEEP) in clinical and functional, including practical nutritional education in other clinical and functional secondary outcomes in cancer patients and survivors. Variables included are: body composition, mediterranean-diet adherence, quality of life (QoL) and functional outcomes (limb functionality, physical activity, physical function and handgrip strength). Furthermore, laboratory variables like muscle thickness (ecography) and muscle activity (electromyography) were included.


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date May 31, 2023
Est. primary completion date May 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - In the case of survivors: Patient who had been surgically treated for their primary tumour with no evidence of recurrence at the time of recruitment. The inclusion of patients undergoing hormonal treatment radiotherapy or antiHER therapy will be allowed. - In the case of cancer patients: patient who had been dignosed by cancer. In both cases, all participants have to maintain the minimum physical function to perform exercise in group. Exclusion Criteria: - Patients were excluded if they had suffered any cardiovascular event defined as stable or unstable angor, acute pulmonary edema, cardiac rhythm disorders, or syncope of cause not affiliated in the year prior to inclusion

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Therapeutic Exercise and Education
Intervention will consisted of 30 minutes of strength exercises followed by 20 minutes of endurance with aerobic training, individualised based on the evaluations of muscular strength and endurance as well as the determination of the aerobic-anaerobic zone transition. Sessions lasted 1 hour, carried out twice a week, during 12 weeks. This intervention will be complemented by nutritional education.

Locations

Country Name City State
Spain Antonio Cuesta Vargas Málaga

Sponsors (1)

Lead Sponsor Collaborator
University of Malaga

Country where clinical trial is conducted

Spain, 

References & Publications (7)

Cantarero-Villanueva I, Fernandez-Lao C, Diaz-Rodriguez L, Cuesta-Vargas AI, Fernandez-de-las-Penas C, Piper BF, Arroyo-Morales M. The Piper Fatigue Scale-Revised: translation and psychometric evaluation in Spanish-speaking breast cancer survivors. Qual Life Res. 2014 Feb;23(1):271-6. doi: 10.1007/s11136-013-0434-5. Epub 2013 May 22. — View Citation

Cuesta-Vargas AI, Buchan J, Arroyo-Morales M. A multimodal physiotherapy programme plus deep water running for improving cancer-related fatigue and quality of life in breast cancer survivors. Eur J Cancer Care (Engl). 2014 Jan;23(1):15-21. doi: 10.1111/ecc.12114. Epub 2013 Aug 16. — View Citation

Cuesta-Vargas AI, Carabantes F, Caracuel Z, Conejo I, Alba E. Effectiveness of an individualized program of muscular strength and endurance with aerobic training for improving germ cell cancer-related fatigue in men undergoing chemotherapy: EFICATEST study protocol for a randomized controlled trial. Trials. 2016 Jan 5;17:8. doi: 10.1186/s13063-015-1143-x. — View Citation

Dethlefsen C, Lillelund C, Midtgaard J, Andersen C, Pedersen BK, Christensen JF, Hojman P. Exercise regulates breast cancer cell viability: systemic training adaptations versus acute exercise responses. Breast Cancer Res Treat. 2016 Oct;159(3):469-79. doi: 10.1007/s10549-016-3970-1. Epub 2016 Sep 6. — View Citation

Gerritsen JK, Vincent AJ. Exercise improves quality of life in patients with cancer: a systematic review and meta-analysis of randomised controlled trials. Br J Sports Med. 2016 Jul;50(13):796-803. doi: 10.1136/bjsports-2015-094787. Epub 2015 Dec 30. — View Citation

Quinten C, Maringwa J, Gotay CC, Martinelli F, Coens C, Reeve BB, Flechtner H, Greimel E, King M, Osoba D, Cleeland C, Ringash J, Schmucker-Von Koch J, Taphoorn MJ, Weis J, Bottomley A. Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. J Natl Cancer Inst. 2011 Dec 21;103(24):1851-8. doi: 10.1093/jnci/djr485. Epub 2011 Dec 7. — View Citation

Roldan-Jimenez C, Bennett P, Cuesta-Vargas AI. Muscular Activity and Fatigue in Lower-Limb and Trunk Muscles during Different Sit-To-Stand Tests. PLoS One. 2015 Oct 27;10(10):e0141675. doi: 10.1371/journal.pone.0141675. eCollection 2015. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Cancer-Related Fatigue (CRF) The Spanish version of the Piper Fatigue Scale-Revised (PFS-R) will be used Prior and after intervention, an average of 3 months
Primary Change from Functional capacity It will be tested by 30-second Sit-To-Stand Test (30-STS), number of repetitions completed. prior and after intervention, an average of 3 months
Primary Change from Upper limb functionality (%) the Spanish version of Upper Limb Functional Index (ULFI) questionnaire will be filled prior and after intervention, an average of 3 months
Primary Change from Lower limb functionality(%) the Spanish version of the Lower Limb Functional Index (LLFI) questionnaire will be filled prior and after intervention, an average of 3 months
Secondary Body Composition BMI, basal metabolism, fat/lean mass and water balance will be measured by Tanita TBF-300A prior and after intervention, an average of 3 months
Secondary Change from Body Mass Index Body Mass Index calculated based on weight and height as: kilogrames (Kg)/ squared meters (Kg/m2) prior and after intervention, an average of 3 months
Secondary Change from Basal Metabolism the number of calories required to keep your body functioning at restm, expressed in Kcal,measured by Tanita TBF-300A prior and after intervention, an average of 3 months
Secondary Change from fat mass The fat mass in the total weight of the body, expressed as Kg, measured by Tanita TBF-300A prior and after intervention, an average of 3 months
Secondary Change from lean mass The lean mass in the total weight of the body, expressed as Kg, measured by Tanita TBF-300A prior and after intervention, an average of 3 months
Secondary Change from water balance Water weight in the total weight of the body, expressed as Kg, measured by Tanita TBF-300A prior and after intervention, an average of 3 months
Secondary Change from Physical activity (METS) The International Physical Activity Questionnaire-Short Form (IPAQ-SF) questionnaire will be employed prior and after intervention, an average of 3 months
Secondary Change from Handgrip Strength (Kg) Strength will be recorded by Jamar Hydraulic Hand Dynamometer Model SH5001 prior and after intervention, an average of 3 months
Secondary Change fromQuality of life (self-reported questionnaire) It will be assessed by The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) version 3.0 prior and after intervention, an average of 3 months
Secondary Change from specific Breast Cancer Quality of life (self-reported questionnaire) It will be assessed by The European Organization for Research and Treatment of Cancer Breast Cancer-Specific Quality of Life questionnaire (EORTC QLQ-BR23) prior and after intervention, an average of 3 months
Secondary Change from Muscle thickness In biceps and cuadriceps muscles, both during relaxation and contraction. prior and after intervention, an average of 3 months
Secondary Change from Grip Strength (dynamometry) maximal handgrip strength measured by a The JamarĀ® Hand Dynamometer (expressed in Kg) prior and after intervention, an average of 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients
Recruiting NCT05318196 - Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases